{
  "variants": [
    {
      "description": "BRAFV600E (Val600Glu)",
      "variant_type": "mutation",
      "significance": "Predictive of response to BRAF inhibitors",
      "frequency": "Found in approximately 50% of cutaneous melanomas",
      "drugs": [
        "Vemurafenib",
        "Dabrafenib"
      ],
      "evidence_level": "A",
      "molecular_effect": "Constitutive activation of the MAPK pathway",
      "clinical_relevance": "Used for treatment selection of BRAF inhibitors",
      "resistance_mechanisms": [
        "BRAF amplifications",
        "MEK1/2 mutations"
      ],
      "biomarker_status": "Predictive",
      "confidence": 0.8,
      "citations": [
        17,
        19,
        22
      ]
    },
    {
      "description": "NRAS mutations (NRASQ61L/R, others)",
      "variant_type": "mutation",
      "significance": "Associated with poor prognosis; may predict response to MEK inhibitors",
      "frequency": "Found in approximately 25% of cutaneous melanomas",
      "drugs": [
        "Binimetinib"
      ],
      "evidence_level": "B",
      "molecular_effect": "Constitutive activation of the MAPK pathway",
      "clinical_relevance": "Potential use for treatment selection of MEK inhibitors",
      "resistance_mechanisms": [],
      "biomarker_status": "Predictive, prognostic",
      "confidence": 0.7,
      "citations": [
        22,
        25,
        107,
        108
      ]
    },
    {
      "description": "NF1 mutations",
      "variant_type": "mutation",
      "significance": "Uncertain",
      "frequency": "Found in approximately 15% of cutaneous melanomas",
      "drugs": [],
      "evidence_level": "D",
      "molecular_effect": "Loss of negative regulation of the MAPK pathway",
      "clinical_relevance": "None established",
      "resistance_mechanisms": [],
      "biomarker_status": "None established",
      "confidence": 0.5,
      "citations": [
        22
      ]
    },
    {
      "description": "KIT mutations (exons 9, 11, 13, 17, 18)",
      "variant_type": "mutation",
      "significance": "May predict response to KIT inhibitors",
      "frequency": "Rare in cutaneous melanoma; more common in acral and mucosal melanomas",
      "drugs": [
        "Imatinib",
        "Nilotinib"
      ],
      "evidence_level": "C",
      "molecular_effect": "Constitutive activation of the KIT receptor tyrosine kinase",
      "clinical_relevance": "Potential use for treatment selection of KIT inhibitors",
      "resistance_mechanisms": [],
      "biomarker_status": "Predictive",
      "confidence": 0.6,
      "citations": [
        109,
        110,
        111,
        112
      ]
    },
    {
      "description": "TERT promoter mutations",
      "variant_type": "mutation",
      "significance": "Associated with poor prognosis",
      "frequency": "Found in 30-80% of melanomas",
      "drugs": [],
      "evidence_level": "B",
      "molecular_effect": "Increased TERT expression and telomerase activity",
      "clinical_relevance": "Prognostic marker",
      "resistance_mechanisms": [],
      "biomarker_status": "Prognostic",
      "confidence": 0.7,
      "citations": [
        41,
        42,
        43
      ]
    },
    {
      "description": "CDKN2A mutations/deletions",
      "variant_type": "mutation",
      "significance": "Associated with melanoma development and progression",
      "frequency": "Frequently altered in melanoma",
      "drugs": [],
      "evidence_level": "B",
      "molecular_effect": "Loss of cell cycle control",
      "clinical_relevance": "None established",
      "resistance_mechanisms": [],
      "biomarker_status": "None established",
      "confidence": 0.7,
      "citations": [
        17,
        22
      ]
    }
  ],
  "clinical_evidence": [
    {
      "description": "therapeutic: Improved PFS and OS compared to BRAF inhibitor monotherapy",
      "evidence_type": "therapeutic",
      "drugs": [
        "Dabrafenib",
        "Trametinib"
      ],
      "trial_phase": "Phase 3 trials",
      "patient_population": "BRAFV600E/K mutation-positive unresectable or metastatic melanoma",
      "line_of_therapy": "First-line",
      "significance": "High",
      "confidence": 0.95,
      "supporting_data": [
        "Median PFS 11-14.9 months",
        "Median OS 22-25 months",
        "3-5 year OS 40%"
      ],
      "biomarker_requirements": [
        "BRAFV600E/K mutation"
      ]
    },
    {
      "description": "therapeutic: Improved PFS and OS compared to ipilimumab monotherapy",
      "evidence_type": "therapeutic",
      "drugs": [
        "Nivolumab",
        "Ipilimumab"
      ],
      "trial_phase": "Phase 3 trials",
      "patient_population": "Unresectable or metastatic melanoma",
      "line_of_therapy": "First-line",
      "significance": "High",
      "confidence": 0.95,
      "supporting_data": [
        "Median PFS 11.5 months",
        "Median OS not reached",
        "3-year OS 58%"
      ],
      "biomarker_requirements": []
    },
    {
      "description": "therapeutic: Improved PFS but not OS compared to dacarbazine",
      "evidence_type": "therapeutic",
      "drugs": [
        "Binimetinib"
      ],
      "trial_phase": "Phase 3 trial",
      "patient_population": "NRAS-mutant advanced melanoma",
      "line_of_therapy": "Second-line or later",
      "significance": "Moderate",
      "confidence": 0.8,
      "supporting_data": [
        "ORR 15% vs 7%",
        "Median PFS 2.8 vs 1.5 months",
        "Median OS 11 vs 10.1 months"
      ],
      "biomarker_requirements": [
        "NRAS mutation"
      ]
    },
    {
      "description": "prognostic: RFS is a valid surrogate marker for OS",
      "evidence_type": "prognostic",
      "drugs": [],
      "trial_phase": "Retrospective analyses",
      "patient_population": "Stage III melanoma after complete resection",
      "line_of_therapy": "Adjuvant",
      "significance": "High",
      "confidence": 0.9,
      "supporting_data": [
        "HR for RFS \u22640.77 correlates with OS benefit"
      ],
      "biomarker_requirements": []
    }
  ],
  "molecular_data": [
    {
      "description": "Pathway: MAPK pathway",
      "pathway": "MAPK pathway",
      "alterations": [
        "BRAF mutations",
        "NRAS mutations",
        "NF1 mutations"
      ],
      "interactions": {
        "upstream": [],
        "downstream": [
          "ERK activation",
          "Cyclin D expression",
          "Transcription factor activation"
        ]
      },
      "therapeutic_implications": [
        "BRAF inhibitors",
        "MEK inhibitors",
        "Resistance via reactivation"
      ],
      "confidence": 0.95
    },
    {
      "description": "Pathway: PI3K-AKT-mTOR pathway",
      "pathway": "PI3K-AKT-mTOR pathway",
      "alterations": [
        "PTEN mutations/loss"
      ],
      "interactions": {
        "upstream": [
          "RTK activation"
        ],
        "downstream": [
          "Increased AKT activation",
          "Increased cell survival, growth, metabolism"
        ]
      },
      "therapeutic_implications": [
        "Potential resistance mechanism to MAPK inhibitors"
      ],
      "confidence": 0.4
    },
    {
      "description": "Pathway: Cell cycle regulation",
      "pathway": "Cell cycle regulation",
      "alterations": [
        "CDKN2A mutations/loss"
      ],
      "interactions": {
        "upstream": [
          "Cyclin D-CDK4/6 activation"
        ],
        "downstream": [
          "Loss of G1/S checkpoint control",
          "Increased cell proliferation"
        ]
      },
      "therapeutic_implications": [],
      "confidence": 0.7
    },
    {
      "description": "Pathway: Telomerase activation",
      "pathway": "Telomerase activation",
      "alterations": [
        "TERT promoter mutations"
      ],
      "interactions": {
        "upstream": [],
        "downstream": [
          "Increased TERT expression",
          "Telomere maintenance"
        ]
      },
      "therapeutic_implications": [],
      "confidence": 0.6
    }
  ],
  "metadata": {
    "timestamp": "2024-12-23 06:22:30.811174",
    "source": "claude-3-opus-20240229",
    "text_length": 80920,
    "processing_time": 84.104879,
    "validation_status": "processed",
    "confidence_scores": {
      "variants": 0.6666666666666666,
      "clinical": 0.9,
      "molecular": 0.6625,
      "overall": 0.7430555555555555
    }
  },
  "stats": {
    "processing_time": 84.53113,
    "text_length": 80920,
    "num_variants": 6,
    "num_clinical_evidence": 4,
    "num_molecular_data": 4,
    "overall_confidence": 0.7430555555555555
  }
}